China Merchants Group participated in a series C-plus round for the cancer and inflammatory disease drug developer.

China-based oncology and inflammatory disease drug developer TransThera Biosciences has received over $50m in a series C-plus round featuring China Merchants Capital, part of conglomerate China Merchants Group, DealStreetAsia reported on Tuesday.

Private equity firm Co-Stone Asset Management led the round, with participation from Summit Capital, a joint fund affiliated with the government-owned State Development and Investment Corp’s SDIC Venture Capital and SDIC Fund Management units.

TransThera is developing small molecule therapeutics designed to address cancer, cardiovascular diseases and liver…